Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roivant Sciences Q1 2025 Adj. EPS $(0.17) Beats $(0.26) Estimate, Sales $55.132M Beat $31.500M Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:08am
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.26) by 34.62 percent. The company reported quarterly sales of $55.132 million which beat the analyst consensus estimate of $31.500 million by 75.02 percent. This is a 154.96 percent increase over sales of $21.624 million the same period last year.

Posted In: ROIV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist